Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Rosario Palacios, Isabel Aguilar, Ana Hidalgo & Jesús Santos. (2006) Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Expert Review of Anti-infective Therapy 4:6, pages 965-971.
Read now
Read now
A Heyer & GA Ogunbanjo. (2006) Adherence to HIV antiretroviral therapy. South African Family Practice 48:8, pages 5-9.
Read now
Read now
J. Santos, R. Palacios, M. López, M.C. Gálvez, F. Lozano, J. de la Torre, M.J. Ríos, L.F. López-Cortés, A. Rivero & M. Torres-Tortosa. (2005) Simplicity and Efficacy of a Once-Daily Antiretroviral Regimen with Didanosine, Lamivudine, and Efavirenz in Naïve Patients: The VESD Study. HIV Clinical Trials 6:6, pages 320-328.
Read now
Read now
Articles from other publishers (8)
Diana Witticke, Hanna M. Seidling, Kristina Lohmann, Alexander F. J. Send & Walter E. Haefeli. (2012) Opportunities to Reduce Medication Regimen Complexity. Drug Safety 36:1, pages 31-41.
Crossref
Crossref
Graeme Moyle, Marta Boffito, Carl Fletcher, Chris Higgs, Phillip E. Hay, Ivy H. Song, Yu Lou, Geoffrey J. Yuen, Sherene S. Min & Elena M. Guerini. (2009) Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects. Antimicrobial Agents and Chemotherapy 53:4, pages 1532-1538.
Crossref
Crossref
Y Yuan, G L'Italien, J Mukherjee & UH Iloeje. (2006) Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort*. HIV Medicine 7:3, pages 156-162.
Crossref
Crossref
Maria Patrizia Carrieri, Catherine Leport, Camelia Protopopescu, Jill-Patrice Cassuto, Elisabeth Bouvet, Dominique Peyramond, Francois Raffi, Jean-Paul Moatti, Geneviéve Cheê & Bruno Spire. (2006) Factors Associated With Nonadherence to Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:4, pages 477-485.
Crossref
Crossref
Urs Karrer, Bruno Ledergerber, Hansjakob Furrer, Luigia Elzi, Manuel Battegay, Matthias Cavassini, Angèle Gayet-Ageron, Bernard Hirschel, Patrick Schmid, Marina Russotti, Rainer Weber & Roberto F Speck. (2005) Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS 19:17, pages 1987-1994.
Crossref
Crossref
F. Pulido, E. Ribera, S. Moreno, A. Muñoz, D. Podzamczer, M. A. del Pozo, A. Rivero, F. Rodríguez, I. Sanjoaquín, R. Teira, P. Viciana, C. Villalonga, A. Antela, J. Carmena, J. Ena, E. Gonzalez, J. M. Kindelán, J. Mallolas, M. Márquez & E. Martínez. (2005) Once-daily antiretroviral therapy: Spanish Consensus Statement. Journal of Antimicrobial Chemotherapy 56:5, pages 808-818.
Crossref
Crossref
Kevin V. Morris & John J. Rossi. 2005. Modern Biopharmaceuticals. Modern Biopharmaceuticals
569
580
.
Chariclia V. Loupa, Michael M. Lederman, Hernán Valdez, Robert A. Salata, Grace A. McComsey, Barbara Gripshover, Scott Fulton, Michelle V. Lisgaris, Michelle Kucia, Robert Asaad, Jennifer Cline & Benigno Rodríguez. (2016) New Entrants to HIV Care Are Presenting Only at Marginally Earlier Stages of Disease but May Increasingly Represent Groups Perceived at Lower Risk. Journal of the International Association of Physicians in AIDS Care 4:2, pages 47-51.
Crossref
Crossref